Conditions: Healthy Volunteers; Asthma
Interventions: Drug: RP3128; Drug: Placebo
Sponsor: Rhizen Pharmaceuticals SA
Recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Meda Pharmaceuticals Announces Launch of Part 3 of the Medikidz Explain Asthma … – PR Newswire (press release)
PR Newswire (press release) |
Meda Pharmaceuticals Announces Launch of Part 3 of the Medikidz Explain Asthma …
PR Newswire (press release) SOMERSET, N.J., Nov. 5, 2015 /PRNewswire/ — Meda Pharmaceuticals (Meda), a leading international specialty pharmaceutical company, announces the launch of Part 3 of the Medikidz Explain Asthma Series, the latest comic book to help families gain an … |
View full post on asthma – Google News
Positive Data Presented on Pieris Pharmaceuticals’ Inhaled Asthma Program at … – Benzinga
|
Positive Data Presented on Pieris Pharmaceuticals' Inhaled Asthma Program at …
Benzinga Prior to joining Pieris Dr. Fitzgerald held senior positions at Argenta Discovery and Pulmagen Therapeutics, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, she was employed … |
View full post on asthma – Google News
Teva Pharmaceuticals New Drug Aims to Reduce Asthma Attacks – Motley Fool
|
Teva Pharmaceuticals New Drug Aims to Reduce Asthma Attacks
Motley Fool Asthma is one of the planet's more common diseases. It affects roughly 300 million people and despite the availability of treatment designed to help reduce asthma attacks, millions of people's asthma is poorly controlled. As a result, a host of … |
View full post on asthma – Google News
FDA approves asthma aerosol developed by Acton Pharmaceuticals – Boston.com
|
FDA approves asthma aerosol developed by Acton Pharmaceuticals
Boston.com Marlborough-based Acton Pharmaceuticals announced Thursday that the Food and Drug Administration has approved its supplemental new drug application for Aerospan Inhalation Aerosol, an asthma treatment for patients 6 years of age and older. Acton Says FDA Oks SNDA For AEROSPAN Inhalation Aerosol For Asthma |
View full post on asthma – Google News
Glenmark Pharmaceuticals receives USFDA tentative nod for anti-asthma tablets – Economic Times
 Moneycontrol.com |
Glenmark Pharmaceuticals receives USFDA tentative nod for anti-asthma tablets
Economic Times NEW DELHI: Glenmark Pharmaceuticals today said it has received tentative approval from the US health regulator to market its generic Montelukast Sodium tablets used for treating asthma and seasonal allergies. Glenmark Generics Inc has received … Glenmark gets tentative US FDA nod for asthma drug Glenmark Generics gets Tentative USFDA nod for Montelukast Sodium 10 mg tablets |
View full post on asthma – Google News
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide … – MarketWatch (press release)
|
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide …
MarketWatch (press release) AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. In this double-blind, placebo-controlled study, … |
View full post on asthma – Google News
Trident Pharmaceuticals Announces Initiation Of Phase 1a – Pharmaceutical Online (press release)
|
Trident Pharmaceuticals Announces Initiation Of Phase 1a
Pharmaceutical Online (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News
Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020 – MarketWatch (press release)
|
Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020
MarketWatch (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News
Theron Pharmaceuticals to Present at the American Thoracic Society Conference … – SunHerald.com
|
Theron Pharmaceuticals to Present at the American Thoracic Society Conference …
SunHerald.com Headquartered in Sunnyvale, California, Theron Pharmaceuticals is committed to developing improved treatments for COPD and asthma. COPD is a slowly developing progressive small airways disease comprised broadly of chronic bronchitis and emphysema, … Theron Pharmaceuticals to Present at the American Thoracic Society Conference … |
View full post on asthma – Google News